Selecta's proprietary SVP™ platform is based on a combination of scientific breakthroughs in immunobiology and nanotechnology. The company's targeted vaccines are designed to optimally interact with the body's immune system to achieve the desired antigen-specific response (rational vaccine design).  Depending on the cellular target and the molecular information encoded in the nanoparticle, the targeted vaccines can potently and specifically induce immune activation or immune tolerance to a broad range of antigens.  The unique characteristics of Selecta's SVP™ product platform are detailed below:

High efficacy.

• Efficient lymph node delivery. The SVP™ is designed to flow freely in the lymphatics to the lymph nodes upon administration and to induce a strong immune response while using lower antigen and adjuvant dosages than conventional vaccines. 
• Controlled stoichiometry and kinetics of adjuvant, antigen, and immunomodulator. Self assembly technology enables SVP™ design variations that are analogous to structure–activity relation analyses used in small molecule research. 
• Proprietary T-Cell activation. Universal helper T-Cell antigens can be integrated within vaccines developed by Selecta to ensure a rapid, robust, and durable immune response.  

Enhanced Safety Profile.

• Selective lymph node targeting. SVP™ efficiently focuses the exposure to vaccine components to the lymphoid tissues, thus minimizing systemic adverse effects.  
• Synthetic nanoparticle. SVP™ contains fully synthetic and clinically validated biodegradable components, avoiding safety issues commonly associated with biologically-derived and conjugated vaccines.

Rational and Modular. Selecta's targeted vaccines can present a wide variety of antigens, including proteins, peptides, oligosaccharides, and small molecules, to treat or prevent a broad spectrum of diseases. Variations of antigen and adjuvant or immunomodulator can be combinatorially optimized in a rational design process. This enables the analysis of structure-activity relationships, leading to more effective and efficient development cycles.

Production Simplicity. Selecta's targeted vaccines can be prototyped and manufactured at scale without the challenges and costs of the complex biological processes that form the basis for conventional vaccines. Furthermore, both cost and time-to-market risks are lower as manufacturing is based upon readily scalable processes using established pharmaceutical unit operations.